Coherus BioSciences, Inc. (CHRS) EPS Estimated At $-0.84; Oppenheimer Holdings Class A (D (OPY) SI Decreased By 12.52%

April 17, 2018 - By Henry Gaston

Oppenheimer Holdings Inc. (NYSE:OPY) Logo

Analysts expect Coherus BioSciences, Inc. (NASDAQ:CHRS) to report $-0.84 EPS on May, 14.They anticipate $0.70 EPS change or 45.45% from last quarter’s $-1.54 EPS. After having $-0.84 EPS previously, Coherus BioSciences, Inc.’s analysts see 0.00% EPS growth. The stock increased 2.16% or $0.275 during the last trading session, reaching $13.025. About 264,258 shares traded. Coherus BioSciences, Inc. (NASDAQ:CHRS) has declined 49.07% since April 17, 2017 and is downtrending. It has underperformed by 60.62% the S&P500.

Oppenheimer Holdings Inc Class A (D (NYSE:OPY) had a decrease of 12.52% in short interest. OPY’s SI was 105,500 shares in April as released by FINRA. Its down 12.52% from 120,600 shares previously. With 64,100 avg volume, 2 days are for Oppenheimer Holdings Inc Class A (D (NYSE:OPY)’s short sellers to cover OPY’s short positions. The SI to Oppenheimer Holdings Inc Class A (D’s float is 1.13%. The stock increased 0.74% or $0.2 during the last trading session, reaching $27.25. About 58,039 shares traded. Oppenheimer Holdings Inc. (NYSE:OPY) has risen 52.24% since April 17, 2017 and is uptrending. It has outperformed by 40.69% the S&P500.

Among 2 analysts covering Oppenheimer Holdings (NYSE:OPY), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Oppenheimer Holdings had 3 analyst reports since September 14, 2015 according to SRatingsIntel. The stock of Oppenheimer Holdings Inc. (NYSE:OPY) earned “Outperform” rating by Macquarie Research on Monday, September 14. The stock of Oppenheimer Holdings Inc. (NYSE:OPY) has “Outperform” rating given on Monday, November 2 by Macquarie Research. The stock of Oppenheimer Holdings Inc. (NYSE:OPY) has “Buy” rating given on Monday, March 21 by Sidoti.

Oppenheimer Holdings Inc. provides middle-market investment banking and full service broker-dealer services and products. The company has market cap of $360.81 million. The firm offers full-service brokerage services covering exchange-traded and over-the-counter corporate equity and debt securities, money market instruments, exchange-traded options and futures contracts, municipal bonds, mutual funds, and unit investment trusts; financial and wealth planning services; and margin lending services. It has a 16.32 P/E ratio. It also provides asset management services, including separately managed accounts, mutual fund managed accounts, discretionary portfolio management programs, fee non-discretionary investment advisory services, alternative investments, portfolio enhancement programs, investment advisory services, and institutional taxable fixed income portfolio management services.

Investors sentiment increased to 2.23 in 2017 Q4. Its up 1.07, from 1.16 in 2017Q3. It is positive, as 2 investors sold Oppenheimer Holdings Inc. shares while 20 reduced holdings. 30 funds opened positions while 19 raised stakes. 5.98 million shares or 12.43% more from 5.32 million shares in 2017Q3 were reported. Schwab Charles Inv Mngmt holds 17,400 shares or 0% of its portfolio. Bridgeway Mgmt Inc holds 67,962 shares or 0.02% of its portfolio. Mufg Americas Corp reported 203 shares or 0% of all its holdings. State Bank Of America De holds 0% or 1,653 shares in its portfolio. Invesco Ltd reported 31,871 shares or 0% of all its holdings. Peak6 Limited Partnership owns 10,621 shares. State Street Corp holds 190,949 shares. Tiaa Cref Invest Management has 0% invested in Oppenheimer Holdings Inc. (NYSE:OPY). Clarivest Asset Mngmt Limited accumulated 18 shares. Deutsche Bancshares Ag accumulated 40,705 shares. Panagora Asset stated it has 3,740 shares. Northern Trust invested in 108,610 shares. Vanguard Group owns 355,662 shares. 215,203 were reported by Millennium Limited Liability Company. Ameritas Inv Ptnrs accumulated 932 shares or 0% of the stock.

Investors sentiment increased to 1.16 in Q4 2017. Its up 0.09, from 1.07 in 2017Q3. It is positive, as 13 investors sold Coherus BioSciences, Inc. shares while 24 reduced holdings. 11 funds opened positions while 32 raised stakes. 49.09 million shares or 5.36% more from 46.59 million shares in 2017Q3 were reported. Teachers Retirement Of The State Of Kentucky has invested 0.02% in Coherus BioSciences, Inc. (NASDAQ:CHRS). Proshare Advsr Llc invested 0% of its portfolio in Coherus BioSciences, Inc. (NASDAQ:CHRS). Macquarie Grp Ltd owns 396,300 shares or 0.01% of their US portfolio. The France-based Axa has invested 0.01% in Coherus BioSciences, Inc. (NASDAQ:CHRS). Credit Suisse Ag invested in 0% or 111,704 shares. D E Shaw holds 0% or 38,106 shares. Barclays Pcl invested in 7,579 shares. Teacher Retirement Sys Of Texas has invested 0% in Coherus BioSciences, Inc. (NASDAQ:CHRS). Ubs Asset Management Americas holds 0.01% or 1.39 million shares in its portfolio. Price T Rowe Assocs Md has invested 0% in Coherus BioSciences, Inc. (NASDAQ:CHRS). Alyeska Lp holds 0.04% of its portfolio in Coherus BioSciences, Inc. (NASDAQ:CHRS) for 484,581 shares. Parallax Volatility Advisers Lp has 0% invested in Coherus BioSciences, Inc. (NASDAQ:CHRS) for 25,022 shares. Retail Bank Of Montreal Can has invested 0% in Coherus BioSciences, Inc. (NASDAQ:CHRS). Highland Cap Mngmt Lp holds 492,330 shares. 25,029 are held by Financial Bank Of America De.

Among 10 analysts covering Coherus Biosciences (NASDAQ:CHRS), 9 have Buy rating, 0 Sell and 1 Hold. Therefore 90% are positive. Coherus Biosciences had 20 analyst reports since September 3, 2015 according to SRatingsIntel. The rating was initiated by Robert W. Baird on Wednesday, October 19 with “Outperform”. Maxim Group maintained the shares of CHRS in report on Friday, March 9 with “Buy” rating. Robert W. Baird maintained the stock with “Buy” rating in Thursday, September 7 report. The firm earned “Buy” rating on Monday, June 12 by Maxim Group. Credit Suisse maintained Coherus BioSciences, Inc. (NASDAQ:CHRS) on Wednesday, September 27 with “Buy” rating. Zacks upgraded the shares of CHRS in report on Thursday, September 3 to “Hold” rating. The rating was maintained by Citigroup on Friday, March 9 with “Buy”. Credit Suisse initiated the shares of CHRS in report on Wednesday, January 20 with “Outperform” rating. Maxim Group initiated it with “Buy” rating and $43 target in Wednesday, September 7 report. On Wednesday, July 27 the stock rating was initiated by Citigroup with “Buy”.

Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The company has market cap of $783.51 million. The company's product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, non?small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. It currently has negative earnings. The Company’s product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, Behçet's Disease, Crohn's Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy.

Oppenheimer Holdings Inc. (NYSE:OPY) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: